Cargando…

Salivary lactoferrin as biomarker for Alzheimer's disease: Brain‐immunity interactions

OBJECTIVE: We aim to explain why salivary lactoferrin (Lf) levels are reduced in patients suffering mild cognitive impairment (MCI) and sporadic Alzheimer's disease (sAD).(1) We also will discuss if such Lf decrease could be due to a downregulation of the sAD associated systemic immunity. BACKG...

Descripción completa

Detalles Bibliográficos
Autores principales: Bermejo‐Pareja, Félix, del Ser, Teodoro, Valentí, Meritxell, de la Fuente, Mónica, Bartolome, Fernando, Carro, Eva
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7984071/
https://www.ncbi.nlm.nih.gov/pubmed/32543760
http://dx.doi.org/10.1002/alz.12107
_version_ 1783667999325028352
author Bermejo‐Pareja, Félix
del Ser, Teodoro
Valentí, Meritxell
de la Fuente, Mónica
Bartolome, Fernando
Carro, Eva
author_facet Bermejo‐Pareja, Félix
del Ser, Teodoro
Valentí, Meritxell
de la Fuente, Mónica
Bartolome, Fernando
Carro, Eva
author_sort Bermejo‐Pareja, Félix
collection PubMed
description OBJECTIVE: We aim to explain why salivary lactoferrin (Lf) levels are reduced in patients suffering mild cognitive impairment (MCI) and sporadic Alzheimer's disease (sAD).(1) We also will discuss if such Lf decrease could be due to a downregulation of the sAD associated systemic immunity. BACKGROUND: Several non‐neurological alterations have been described in sAD, mainly in skin, blood cell, and immunological capacities. We reviewed briefly the main pathophysiological theories of sAD (amyloid cascade, tau, unfolder protein tau, and amyloid deposits) emphasizing the most brain based hypotheses such as the updated tau‐related neuron skeletal hypothesis; we also comment on the systemic theories that emphasize the fetal origin of the complex disorders that include the low inflammatory and immunity theories of sAD. NEW/UPDATED HYPOTHESIS: Lf has important anti‐infectious and immunomodulatory roles in health and disease. We present the hypothesis that the reduced levels of saliva Lf could be an effect of immunological disturbances associated to sAD. Under this scenario, two alternative pathways are possible: first, whether sAD could be a systemic disorder (or disorders) related to early immunological and low inflammatory alterations; second, if systemic immunity alterations of sAD manifestations could be downstream of early sAD brain affectations. MAJOR CHALLENGES FOR THE HYPOTHESIS: The major challenge of the Lf as early sAD biomarker would be its validation in other clinical and population‐based studies. It is possible the decreased salivary Lf in early sAD could be related to immunological modulation actions, but other different unknown mechanisms could be the origin of such reduction. LINKAGE TO OTHER MAJOR THEORIES: This hypothesis is in agreement with two physiopathological explanations of the sAD as a downstream process determined by the early lesions of the hypothalamus and autonomic vegetative system (neurodegeneration), or as a consequence of low neuroinflammation and dysimmunity since the early life aggravated in the elderly (immunosenescence).
format Online
Article
Text
id pubmed-7984071
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-79840712021-03-24 Salivary lactoferrin as biomarker for Alzheimer's disease: Brain‐immunity interactions Bermejo‐Pareja, Félix del Ser, Teodoro Valentí, Meritxell de la Fuente, Mónica Bartolome, Fernando Carro, Eva Alzheimers Dement Theoretical Article OBJECTIVE: We aim to explain why salivary lactoferrin (Lf) levels are reduced in patients suffering mild cognitive impairment (MCI) and sporadic Alzheimer's disease (sAD).(1) We also will discuss if such Lf decrease could be due to a downregulation of the sAD associated systemic immunity. BACKGROUND: Several non‐neurological alterations have been described in sAD, mainly in skin, blood cell, and immunological capacities. We reviewed briefly the main pathophysiological theories of sAD (amyloid cascade, tau, unfolder protein tau, and amyloid deposits) emphasizing the most brain based hypotheses such as the updated tau‐related neuron skeletal hypothesis; we also comment on the systemic theories that emphasize the fetal origin of the complex disorders that include the low inflammatory and immunity theories of sAD. NEW/UPDATED HYPOTHESIS: Lf has important anti‐infectious and immunomodulatory roles in health and disease. We present the hypothesis that the reduced levels of saliva Lf could be an effect of immunological disturbances associated to sAD. Under this scenario, two alternative pathways are possible: first, whether sAD could be a systemic disorder (or disorders) related to early immunological and low inflammatory alterations; second, if systemic immunity alterations of sAD manifestations could be downstream of early sAD brain affectations. MAJOR CHALLENGES FOR THE HYPOTHESIS: The major challenge of the Lf as early sAD biomarker would be its validation in other clinical and population‐based studies. It is possible the decreased salivary Lf in early sAD could be related to immunological modulation actions, but other different unknown mechanisms could be the origin of such reduction. LINKAGE TO OTHER MAJOR THEORIES: This hypothesis is in agreement with two physiopathological explanations of the sAD as a downstream process determined by the early lesions of the hypothalamus and autonomic vegetative system (neurodegeneration), or as a consequence of low neuroinflammation and dysimmunity since the early life aggravated in the elderly (immunosenescence). John Wiley and Sons Inc. 2020-06-16 2020-08 /pmc/articles/PMC7984071/ /pubmed/32543760 http://dx.doi.org/10.1002/alz.12107 Text en © 2020 The Authors. Alzheimer's & Dementia published by Wiley Periodicals LLC on behalf of Alzheimer's Association This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
spellingShingle Theoretical Article
Bermejo‐Pareja, Félix
del Ser, Teodoro
Valentí, Meritxell
de la Fuente, Mónica
Bartolome, Fernando
Carro, Eva
Salivary lactoferrin as biomarker for Alzheimer's disease: Brain‐immunity interactions
title Salivary lactoferrin as biomarker for Alzheimer's disease: Brain‐immunity interactions
title_full Salivary lactoferrin as biomarker for Alzheimer's disease: Brain‐immunity interactions
title_fullStr Salivary lactoferrin as biomarker for Alzheimer's disease: Brain‐immunity interactions
title_full_unstemmed Salivary lactoferrin as biomarker for Alzheimer's disease: Brain‐immunity interactions
title_short Salivary lactoferrin as biomarker for Alzheimer's disease: Brain‐immunity interactions
title_sort salivary lactoferrin as biomarker for alzheimer's disease: brain‐immunity interactions
topic Theoretical Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7984071/
https://www.ncbi.nlm.nih.gov/pubmed/32543760
http://dx.doi.org/10.1002/alz.12107
work_keys_str_mv AT bermejoparejafelix salivarylactoferrinasbiomarkerforalzheimersdiseasebrainimmunityinteractions
AT delserteodoro salivarylactoferrinasbiomarkerforalzheimersdiseasebrainimmunityinteractions
AT valentimeritxell salivarylactoferrinasbiomarkerforalzheimersdiseasebrainimmunityinteractions
AT delafuentemonica salivarylactoferrinasbiomarkerforalzheimersdiseasebrainimmunityinteractions
AT bartolomefernando salivarylactoferrinasbiomarkerforalzheimersdiseasebrainimmunityinteractions
AT carroeva salivarylactoferrinasbiomarkerforalzheimersdiseasebrainimmunityinteractions